CCTG

CO.26

NCT02870920

CO26

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies

Status:

Closed to Accrual

26459-200.png

II

Phase

Line of Therapy.png

Palliative

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Durvalumab +Tremelimumab

Treatment Arms

o Experimental: Durvalumab plus Tremelimumab and Best Supportive Care

o Active Comparator: Best Supportive Care